Dextrose injection contain source of water and calories, and is capable of inducing diuresis depending on the clinical condition of the patient. Dextrose injections are sterile, non-pyrogenic, and does not contain bacteriostatic or antimicrobial agents. It is intended for intravenous administration. This intravenous solution is indicated for use in adults and pediatric patients as sources of calories and water for hydration. Dosage of dextrose injection is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations.
Increasing launches and approval of novel products, increasing adoption of inorganic growth strategies such as collaboration and acquisition by key players operating in the market and rising demand for dextrose for first-aid treatment as instant nutrition therapy in critical care are expected to drive the growth of global dextrose injection market over the forecast period. For instance, in July 2015, B. Braun Medical Inc. received the U.S. Food and Drug Administration approval for 70% Dextrose for Injection in a 2L flexible container.
- This report provides in-depth analysis of the global dextrose injection market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dextrose injection market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer Inc., Amphastar Pharmaceuticals Inc., Shangai Haixin group Co. Ltd., Seqirus GmbH, Baxter International Inc., Shandong Qidu Pharmaceutical, Sanctus drugs and pharmaceuticals Pvt., Hospira Inc., B Braun Medical Ltd., Aurobindo Pharmaceuticals Ltd., and SteriMAx Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dextrose injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dextrose injection market
-
- 5% Dextrose Injection
- 10% Dextrose Injection
- 50% Dextrose Injection
- 70% Dextrose Injection
- Others
-
- First-aid Treatment
- Sports
- Trophotherapy
- Others
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Pfizer Inc
- Amphastar Pharmaceuticals Inc
- Shangai Haixin group Co Ltd
- Seqirus GmbH, Baxter International Inc
- Shandong Qidu Pharmaceutical
- Sanctus drugs and pharmaceuticals Pvt
- Hospira Inc., B Braun Medical Ltd
- Aurobindo Pharmaceuticals Ltd
- SteriMAx Inc
